



*Paris, 6 April 2016, 6.30pm*

**AB Science will host live webcast on phase 3 interim analysis in ALS  
on 8 April 2016, from 5.30pm to 6.30pm CET**

**AB Science SA** (NYSE Euronext – FR0010557264 – AB), a pharmaceutical company specialized in research, development and marketing of protein kinase inhibitors (PKIs), is hosting a live webcast on the phase 3 interim analysis results of masitinib in the treatment of amyotrophic lateral sclerosis (ALS) with key opinion leaders from this disease.

The webcast call will be held on Friday 8 April 2016 from 5.30pm to 6.30pm CET.

The web conference will provide the opportunity to understand:

- The design of the phase 3 study
- The outcome of the interim analysis and its implication for the study, in particular:
  - o Why is the study not stopped
  - o Why is the treatment effect at the interim analysis not disclosed
- The next steps anticipated with regulatory agencies
- The interpretation of the results on:
  - o Primary analysis
  - o Sensitivity analysis
  - o Secondary endpoints
  - o Safety
- The mechanism of action of masitinib in ALS
- The current IP position of masitinib in ALS
- Incidence and prevalence of ALS

It will be followed by a Q&A session with the management and KOL participating to the study.

The following experts in this disease will participate:

- Dr Jesus S. Mora, international coordinator of the study  
ALS Unit, Hospital Carlos III  
Madrid, Spain
- Dr Angela Genge  
Montreal Neurological Institute and Hospital  
Montreal, Canada
- Dr Conrado Estol  
STAT Research  
Buenos Aires, Argentina
- Dr Adriano Chiol  
AO città della salute e della scienza di Torino-ospedale le Molinette  
Torino, Italy
- Dr Luis Barbeito  
Institut Pasteur de Montevideo  
Montevideo, Uruguay
- Pr Olivier Hermine  
Division of Hematology/Oncology, Necker University Hospital  
Paris, France

**About masitinib**

Masitinib is a new orally administered tyrosine kinase inhibitor that targets mast cells and macrophages, important cells for immunity, through inhibiting a limited number of kinases. Based on its unique mechanism of action, masitinib can be developed in a large number of conditions in oncology, in inflammatory diseases, and in certain diseases of the central nervous system. In oncology due to its immunotherapy effect, masitinib can have an effect on survival, alone or in combination with chemotherapy. Through its activity on mast cells and microglia and consequently the inhibition of the activation of the inflammatory process, masitinib can have an effect on the symptoms associated with some inflammatory and central nervous system diseases and the degeneration of these diseases.

**About AB Science**

Founded in 2001, AB Science is a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), a class of targeted proteins whose action are key in signaling pathways within cells. Our programs target only diseases with high unmet medical needs, often lethal with short term survival or rare or refractory to previous lines of treatment in cancers, inflammatory diseases, and central nervous system diseases, both in human and animal health.

AB Science has developed a proprietary portfolio of molecules and the Company's lead compound, masitinib, has already been registered for veterinary medicine in Europe and in the USA. The company is currently pursuing twelve phase 3 studies in human medicine in first-line and second-line GIST, metastatic melanoma expressing JM mutation of c-Kit, multiple myeloma, metastatic colorectal cancer, metastatic prostate cancer, pancreatic cancer, mastocytosis, severe asthma uncontrolled by oral corticosteroid, Alzheimer's Disease, progressive forms of multiple sclerosis, and amyotrophic lateral sclerosis. The company is headquartered in Paris, France, and listed on Euronext Paris (ticker: AB).

Further information is available on AB Science's website: [www.ab-science.com](http://www.ab-science.com)

*This document contains prospective information. No guarantee can be given as for the realization of these forecasts, which are subject to those risks described in documents deposited by the Company to the Authority of the financial markets, including trends of the economic conjuncture, the financial markets and the markets on which AB Science is present.*

\* \* \*

AB Science - Financial Communication & Media Relations  
[investors@ab-science.com](mailto:investors@ab-science.com)